Authors:

Harshini Asogan¹ MD, Issa Al Salmi^2,3* MD, FRCPI, MRCP (UK), FRCP, MIPH, PHD (AUS), FASN (USA), Divij Krishna Jha² MD, Fatma Al Rahbi² and Suad Hannawi⁴ MD, MRCP (UK), FRCP, MIPH, PHD (AUS)

The Royal Hospital, 23 July Street, P O Box 1331, code 111, Muscat, Oman

Abstract:

1.1. Introduction: Beta2-microglobulin (β-2M) production is constant among healthy population, making it appropriate proxy for the estimated Glomerular-Filtration-Rate (eGFR).

1.2. Methodology: This clinical observational study was conducted at the Royal Hospital, Muscat. It aims to define the level of serum-β-2M along with their clinical and investigatory profiles. Data collected prospectively via electronic system.

1.3. Results: 866 had Chronic-Kidney-Disease (CKD), of which 476 (55%) were males. A total of 552 had stage-1CKD with β-2M (mg/dl) levels found to be 3.04(5) in 287 male patients and 2.68(3.9) in 265 females. Stage-2 CKD, a total of 121 patients with 69 males and 52 females had β-2M levels 4.15 (2.9) and 4.06 (3.3) respectively. A total of 91 patients with Stage-3CKD, of which 61 were males and 30 were females, with β-2M levels being 7.14 (5.3) and 8.96 (7.2) respectively.

1.4. Conclusions: Kidney-function is the main determinant of serum β-2M by affecting both filtration via glomeruli of the kidney and the generation of β-2M. Uremic solutes that are retained in kidney failure institutes a key cause for the sharp increase of β-2M in CKD. Management strategies for various hematological disorders, in particular during chemotherapy, need to take into consideration maintenance of a good kidney-function

Keywords:

Beta2-Microglobulin (β-2M); estimated GlomerularFiltration-Rate (eGFR); Chronic-Kidney-Disease (CKD); Uremic solutes; Multiple Myeloma; Hodgkin’s lymphoma; Non-Hodgkin’s Lymphoma; Solid Tumors

Citation:

Issa Al Salmi. Beta-2-Microglobulin Level Increases with Advanced CKD Stages: The Implications and Significance. World Journal of Medical Oncology 2020.